MarginsXMarginsX
Home › Markets › Health Care › GELS

Gelteq Limited (GELS)

GELS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.3589
-5.63% on the day
Market cap
$3.8M
Nano cap
Revenue
No annual revenue in SEC XBRL data for this filer
Net income
No annual revenue in SEC XBRL data for this filer

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerGELS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryAustralia
IPO year2024
SEC CIK0001920092
SEC industry codePharmaceutical Preparations
Incorporated inAustralia

Financials

No annual revenue in SEC XBRL data for this filer.

Warning signs

Cash runway
not enough data
Share count, 1 year
See the dilution note
Going-concern doubt
Yes
20-F filed November 17, 2025
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"As discussed in Note 4 to the consolidated financial statements, the Company has an excess of current liabilities over current assets and suffered net loss from operations, which raises substantial doubt about its ability to continue as a going concern."
20-F 2025-11-17
Cash and burnnot enough dataNone on EDGAR
Shares outstandingNo cover-page share count in XBRLNone on EDGAR
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorM&K CPAS, PLLC, The Woodlands, Texas, United StatesPCAOB Form AP 2025-11-24
Late filings, 12 months1 NT noticeNT 20-F 2026-11-02
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-06-30
Not filed-$6.6MNot filedNot filedNo debt tagsNeeds four quarters20-F 2025-11-17
FY 2024
2024-06-30
Not filed-$3.5MNot filedNot filedNo debt tagsNeeds four quarters20-F 2025-11-17

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS
424B32025-08-29
Latest annual report
ANNUAL REPORT
20-F2026-11-16
Latest quarterly / interim
REPORT OF FOREIGN PRIVATE ISSUER
6-K2026-07-06

Source: SEC EDGAR submissions feed, 73 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-13.6%
1 month-20.8%
3 months-34.6%
Year to date-52.5%
1 year-62.4%
From 52-week high-75.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
IMNNImunon Inc.$0.5940-5.56%$3.9M
AZTRAzitra Inc$0.6270+3.06%$3.8M
XTLBXTL Biopharmaceuticals Ltd.$1.54-3.75%$3.8M
TRAWTraws Pharma Inc.$0.2600+3.59%$4.0M
XBIOXenetic Biosciences Inc.$1.49-10.24%$3.5M
BGMSBio Green Med Solution Inc.$0.6502+1.55%$4.3M
KPRXKiora Pharmaceuticals Inc.$0.9820-20.16%$4.3M
SILOSilo Pharma Inc.$1.57-14.40%$3.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier